SBFM

Sunshine Biopharma Inc.

2.71

USD

-0.08

-2.87%

Nov 06, 15:59 UTC -5

Closed

After-Market

2.77

+0.06

+2.25%

Sunshine Biopharma Inc. (SBFM) Earnings

SBFM Earnings Reports

Positive Surprise Ratio

SBFM beat 1 of 9 last estimates.

11%

Next Report

Next Week

Date of Next Report

Nov 11, 2026

Estimate for Q3 26 (Revenue/ EPS)

$9.79M

-$3.46

Implied change from Q2 26 (Revenue/ EPS)

Implied change from Q3 25 (Revenue/ EPS)

+3.98%

+82.11%

Sunshine Biopharma Inc. earnings per share and revenue

On Aug 13, 2026, SBFM reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.

Looking ahead to Q3 26, -- analysts forecast an EPS of -3.46 USD, with revenue projected to reach 9.79 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

INmune Bio Inc. Common stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.14

Actual

-$0.17

Surprise

-13.64%

Moderna, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$1.27

Actual

$0.38

Surprise

+129.79%

Vera Therapeutics, Inc. Class A Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$1.65

Actual

-$1.30

Surprise

+21.33%

Novavax Inc

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.34

Actual

-$0.19

Surprise

+44.56%

Eton Pharmaceutcials, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.31

Actual

$1.06

Surprise

+232.50%

Castle Biosciences, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.37

Actual

-$0.13

Surprise

+65.32%

Monte Rosa Therapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.29

Actual

$0.03

Surprise

+110.09%

PUMA BIOTECHNOLOGY INC

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.09

Actual

$0.15

Surprise

+63.40%

Allogene Therapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.15

Actual

-$0.15

Surprise

+0.33%

Arcturus Therapeutics Holdings Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.69

Actual

-$0.26

Surprise

+62.44%

FAQ

What were Sunshine Biopharma Inc.'s earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Sunshine Biopharma Inc. reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.

How did the market react to Sunshine Biopharma Inc.'s Q2 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Sunshine Biopharma Inc. expected to report next?

The next earning report is scheduled for Nov 11, 2026.

What are the forecasts for Sunshine Biopharma Inc.'s next earnings report?

Based on -- analysts, Sunshine Biopharma Inc. is expected to report EPS of -$3.46 and revenue of $9.79M for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.